Bank of America just raised its EUR/USD forecast
Phreesia, Inc. (NYSE:PHR), a $1.4 billion healthcare software company with a "GREAT" InvestingPro financial health rating, recently saw its Principal Accounting Officer, Yvonne Hui, divest a significant portion of her holdings in the company. According to a recent SEC filing, Hui sold shares in two separate transactions over the course of two days, resulting in a total sale value of $109,885.
On April 8, Hui sold 1,148 shares at a price range of $23.4568 to $23.995 per share and an additional 730 shares at a price range of $24.00 to $24.915 per share. These transactions amounted to a total of $44,795. The following day, on April 9, she sold 2,802 shares at a price of $23.23 each, totaling $65,090. The current trading price of $24.01 suggests the stock is slightly undervalued according to InvestingPro Fair Value metrics.
These sales were conducted under Phreesia's mandatory sell-to-cover policy to cover tax withholding obligations related to restricted stock units. After these transactions, Hui retains ownership of 25,647 shares in the company. While currently unprofitable, analysts tracked by InvestingPro expect Phreesia to achieve profitability this year, with multiple analysts revising earnings estimates upward. Get access to 6 more exclusive ProTips and comprehensive analysis in the Pro Research Report.
In other recent news, Phreesia Inc . has been the focus of several analyst reports following its fourth-quarter fiscal year 2025 results. DA Davidson reiterated a Buy rating with a $36.00 price target, highlighting the company's undervaluation and consistent performance in the U.S. healthcare services sector. Meanwhile, Jefferies raised its price target for Phreesia from $28.00 to $32.00, maintaining a Buy rating and expressing confidence in Phreesia's growth prospects and operational leverage. KeyBanc Capital Markets also maintained an Overweight rating with a $30.00 price target, citing significant margin improvement and strong top-line growth.
Raymond (NSE:RYMD) James kept an Outperform rating with a $30.00 price target, focusing on Phreesia's transition to a free cash flow-oriented growth strategy. This strategy is expected to enhance the conversion of earnings into cash flow. Analysts from these firms have noted the company's strategic shift towards Network Solutions as a key driver for future growth and margin expansion. The various price targets and ratings reflect a broad consensus among analysts about Phreesia's potential for continued growth and profitability. These developments come amid a backdrop of increased attention to the valuation challenges in the B2B marketplace sector, as highlighted by JMP Securities.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.